Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695009 | 1.00 | GPR119 (0.47) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2729370 | 1.00 | GPR119 (0.47) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2718091 | 0.91 | PIK3CD (0.49) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2717491 | 0.91 | PIK3CD (0.49) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2717489 | 0.91 | PIK3CD (0.49) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2719120 | 0.90 | GPR119 (0.43) | GPR119PIK3CDCYP2C9 | |
| SCHEMBL2716635 | 0.90 | GPR119 (0.47) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2716633 | 0.90 | GPR119 (0.47) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2718185 | 0.89 | GPR119 (0.49) | GPR119PIK3CDCYP2C9 | |
| SCHEMBL2715717 | 0.89 | GPR119 (0.49) | GPR119PIK3CDCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | claimed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | claimed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | claimed |
| EP-2445904-A1 | NOVEL GPR 119 AGONISTS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | claimed |
| WO-2010146605-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-23 | — | — | WO | claimed |
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | disclosed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR4, GPR39 | GPR119 1/4885PIK3CD 2076/4885PIK3CA 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.